The global Gene Therapy On Cardiovascular Disease market size was valued at USD 13 million in 2022 and is forecast to a readjusted size of USD 1073.1 million by 2029 with a CAGR of 87.1% during review period.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.
This report is a detailed and comprehensive analysis for global Gene Therapy On Cardiovascular Disease market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Gene Therapy On Cardiovascular Disease market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Therapy On Cardiovascular Disease
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Gene Therapy On Cardiovascular Disease market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
bluebird bio
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Viral Gene Therapy
Non-Viral Gene Therapy
Heart Disease
Vascular Disease
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Gene Therapy On Cardiovascular Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapy On Cardiovascular Disease, with revenue, gross margin and global market share of Gene Therapy On Cardiovascular Disease from 2018 to 2023.
Chapter 3, the Gene Therapy On Cardiovascular Disease competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy On Cardiovascular Disease market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy On Cardiovascular Disease.
Chapter 13, to describe Gene Therapy On Cardiovascular Disease research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Gene Therapy On Cardiovascular Disease
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Therapy On Cardiovascular Disease by Type
1.3.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type in 2022
1.3.3 Viral Gene Therapy
1.3.4 Non-Viral Gene Therapy
1.4 Global Gene Therapy On Cardiovascular Disease Market by Application
1.4.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Heart Disease
1.4.3 Vascular Disease
1.5 Global Gene Therapy On Cardiovascular Disease Market Size & Forecast
1.6 Global Gene Therapy On Cardiovascular Disease Market Size and Forecast by Region
1.6.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region, (2018-2029)
1.6.3 North America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
1.6.4 Europe Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
1.6.6 South America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Gene Therapy On Cardiovascular Disease Product and Solutions
2.1.4 Biogen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Biogen Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Gene Therapy On Cardiovascular Disease Product and Solutions
2.2.4 Novartis Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business
2.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions
2.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Gilead Sciences Recent Developments and Future Plans
2.4 Sarepta Therapeutics
2.4.1 Sarepta Therapeutics Details
2.4.2 Sarepta Therapeutics Major Business
2.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
2.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Sarepta Therapeutics Recent Developments and Future Plans
2.5 Alnylam Pharmaceuticals
2.5.1 Alnylam Pharmaceuticals Details
2.5.2 Alnylam Pharmaceuticals Major Business
2.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions
2.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.6 Amgen
2.6.1 Amgen Details
2.6.2 Amgen Major Business
2.6.3 Amgen Gene Therapy On Cardiovascular Disease Product and Solutions
2.6.4 Amgen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amgen Recent Developments and Future Plans
2.7 Spark Therapeutics
2.7.1 Spark Therapeutics Details
2.7.2 Spark Therapeutics Major Business
2.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
2.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Spark Therapeutics Recent Developments and Future Plans
2.8 Akcea Therapeutics
2.8.1 Akcea Therapeutics Details
2.8.2 Akcea Therapeutics Major Business
2.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
2.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Akcea Therapeutics Recent Developments and Future Plans
2.9 bluebird bio
2.9.1 bluebird bio Details
2.9.2 bluebird bio Major Business
2.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions
2.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 bluebird bio Recent Developments and Future Plans
2.10 Sunway Biotech
2.10.1 Sunway Biotech Details
2.10.2 Sunway Biotech Major Business
2.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions
2.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Sunway Biotech Recent Developments and Future Plans
2.11 SIBIONO
2.11.1 SIBIONO Details
2.11.2 SIBIONO Major Business
2.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions
2.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 SIBIONO Recent Developments and Future Plans
2.12 AnGes
2.12.1 AnGes Details
2.12.2 AnGes Major Business
2.12.3 AnGes Gene Therapy On Cardiovascular Disease Product and Solutions
2.12.4 AnGes Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 AnGes Recent Developments and Future Plans
2.13 Orchard Therapeutics
2.13.1 Orchard Therapeutics Details
2.13.2 Orchard Therapeutics Major Business
2.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
2.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Orchard Therapeutics Recent Developments and Future Plans
2.14 Human Stem Cells Institute
2.14.1 Human Stem Cells Institute Details
2.14.2 Human Stem Cells Institute Major Business
2.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions
2.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Human Stem Cells Institute Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Gene Therapy On Cardiovascular Disease Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Gene Therapy On Cardiovascular Disease by Company Revenue
3.2.2 Top 3 Gene Therapy On Cardiovascular Disease Players Market Share in 2022
3.2.3 Top 6 Gene Therapy On Cardiovascular Disease Players Market Share in 2022
3.3 Gene Therapy On Cardiovascular Disease Market: Overall Company Footprint Analysis
3.3.1 Gene Therapy On Cardiovascular Disease Market: Region Footprint
3.3.2 Gene Therapy On Cardiovascular Disease Market: Company Product Type Footprint
3.3.3 Gene Therapy On Cardiovascular Disease Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Gene Therapy On Cardiovascular Disease Consumption Value and Market Share by Type (2018-2023)
4.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2023)
5.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Application (2024-2029)
6 North America
6.1 North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
6.2 North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country
6.3.1 North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
6.3.2 United States Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
6.3.3 Canada Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
6.3.4 Mexico Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
7.2 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country
7.3.1 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
7.3.2 Germany Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
7.3.3 France Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
7.3.5 Russia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
7.3.6 Italy Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region
8.3.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2029)
8.3.2 China Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8.3.3 Japan Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8.3.4 South Korea Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8.3.5 India Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
8.3.7 Australia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
9 South America
9.1 South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
9.2 South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
9.3 South America Gene Therapy On Cardiovascular Disease Market Size by Country
9.3.1 South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
9.3.2 Brazil Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
9.3.3 Argentina Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country
10.3.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
10.3.2 Turkey Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
10.3.4 UAE Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Gene Therapy On Cardiovascular Disease Market Drivers
11.2 Gene Therapy On Cardiovascular Disease Market Restraints
11.3 Gene Therapy On Cardiovascular Disease Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Gene Therapy On Cardiovascular Disease Industry Chain
12.2 Gene Therapy On Cardiovascular Disease Upstream Analysis
12.3 Gene Therapy On Cardiovascular Disease Midstream Analysis
12.4 Gene Therapy On Cardiovascular Disease Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Gene Therapy On Cardiovascular Disease Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Gene Therapy On Cardiovascular Disease Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Biogen Company Information, Head Office, and Major Competitors
Table 6. Biogen Major Business
Table 7. Biogen Gene Therapy On Cardiovascular Disease Product and Solutions
Table 8. Biogen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Biogen Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Gene Therapy On Cardiovascular Disease Product and Solutions
Table 13. Novartis Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 16. Gilead Sciences Major Business
Table 17. Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions
Table 18. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Gilead Sciences Recent Developments and Future Plans
Table 20. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 21. Sarepta Therapeutics Major Business
Table 22. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
Table 23. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Sarepta Therapeutics Recent Developments and Future Plans
Table 25. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 26. Alnylam Pharmaceuticals Major Business
Table 27. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions
Table 28. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Alnylam Pharmaceuticals Recent Developments and Future Plans
Table 30. Amgen Company Information, Head Office, and Major Competitors
Table 31. Amgen Major Business
Table 32. Amgen Gene Therapy On Cardiovascular Disease Product and Solutions
Table 33. Amgen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Amgen Recent Developments and Future Plans
Table 35. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 36. Spark Therapeutics Major Business
Table 37. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
Table 38. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Spark Therapeutics Recent Developments and Future Plans
Table 40. Akcea Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Akcea Therapeutics Major Business
Table 42. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
Table 43. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Akcea Therapeutics Recent Developments and Future Plans
Table 45. bluebird bio Company Information, Head Office, and Major Competitors
Table 46. bluebird bio Major Business
Table 47. bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions
Table 48. bluebird bio Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. bluebird bio Recent Developments and Future Plans
Table 50. Sunway Biotech Company Information, Head Office, and Major Competitors
Table 51. Sunway Biotech Major Business
Table 52. Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions
Table 53. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Sunway Biotech Recent Developments and Future Plans
Table 55. SIBIONO Company Information, Head Office, and Major Competitors
Table 56. SIBIONO Major Business
Table 57. SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions
Table 58. SIBIONO Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. SIBIONO Recent Developments and Future Plans
Table 60. AnGes Company Information, Head Office, and Major Competitors
Table 61. AnGes Major Business
Table 62. AnGes Gene Therapy On Cardiovascular Disease Product and Solutions
Table 63. AnGes Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. AnGes Recent Developments and Future Plans
Table 65. Orchard Therapeutics Company Information, Head Office, and Major Competitors
Table 66. Orchard Therapeutics Major Business
Table 67. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
Table 68. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Orchard Therapeutics Recent Developments and Future Plans
Table 70. Human Stem Cells Institute Company Information, Head Office, and Major Competitors
Table 71. Human Stem Cells Institute Major Business
Table 72. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions
Table 73. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Human Stem Cells Institute Recent Developments and Future Plans
Table 75. Global Gene Therapy On Cardiovascular Disease Revenue (USD Million) by Players (2018-2023)
Table 76. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players (2018-2023)
Table 77. Breakdown of Gene Therapy On Cardiovascular Disease by Company Type (Tier 1, Tier 2, and Tier 3)
Table 78. Market Position of Players in Gene Therapy On Cardiovascular Disease, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 79. Head Office of Key Gene Therapy On Cardiovascular Disease Players
Table 80. Gene Therapy On Cardiovascular Disease Market: Company Product Type Footprint
Table 81. Gene Therapy On Cardiovascular Disease Market: Company Product Application Footprint
Table 82. Gene Therapy On Cardiovascular Disease New Market Entrants and Barriers to Market Entry
Table 83. Gene Therapy On Cardiovascular Disease Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Gene Therapy On Cardiovascular Disease Consumption Value (USD Million) by Type (2018-2023)
Table 85. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Type (2018-2023)
Table 86. Global Gene Therapy On Cardiovascular Disease Consumption Value Forecast by Type (2024-2029)
Table 87. Global Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023)
Table 88. Global Gene Therapy On Cardiovascular Disease Consumption Value Forecast by Application (2024-2029)
Table 89. North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
Table 90. North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
Table 91. North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
Table 92. North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
Table 93. North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
Table 94. North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
Table 95. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
Table 98. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
Table 99. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
Table 102. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
Table 103. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
Table 104. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
Table 105. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2023) & (USD Million)
Table 106. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2024-2029) & (USD Million)
Table 107. South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
Table 108. South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
Table 109. South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
Table 110. South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
Table 111. South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
Table 112. South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
Table 114. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
Table 115. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
Table 116. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
Table 117. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
Table 118. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
Table 119. Gene Therapy On Cardiovascular Disease Raw Material
Table 120. Key Suppliers of Gene Therapy On Cardiovascular Disease Raw Materials
List of Figures
Figure 1. Gene Therapy On Cardiovascular Disease Picture
Figure 2. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type in 2022
Figure 4. Viral Gene Therapy
Figure 5. Non-Viral Gene Therapy
Figure 6. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application in 2022
Figure 8. Heart Disease Picture
Figure 9. Vascular Disease Picture
Figure 10. Global Gene Therapy On Cardiovascular Disease Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Gene Therapy On Cardiovascular Disease Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Gene Therapy On Cardiovascular Disease Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region in 2022
Figure 15. North America Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players in 2022
Figure 21. Gene Therapy On Cardiovascular Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Gene Therapy On Cardiovascular Disease Market Share in 2022
Figure 23. Global Top 6 Players Gene Therapy On Cardiovascular Disease Market Share in 2022
Figure 24. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Type (2018-2023)
Figure 25. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Type (2024-2029)
Figure 26. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Application (2018-2023)
Figure 27. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Application (2024-2029)
Figure 28. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 38. France Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region (2018-2029)
Figure 45. China Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 48. India Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
Figure 62. Gene Therapy On Cardiovascular Disease Market Drivers
Figure 63. Gene Therapy On Cardiovascular Disease Market Restraints
Figure 64. Gene Therapy On Cardiovascular Disease Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Gene Therapy On Cardiovascular Disease in 2022
Figure 67. Manufacturing Process Analysis of Gene Therapy On Cardiovascular Disease
Figure 68. Gene Therapy On Cardiovascular Disease Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
